MELT-300

Phase 2Small molecule

MMelt Pharmaceuticals

MELT-300 is one of 29 small molecule programs targeting Cataract. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CataractActive, not recruiting

CataractPhase 2

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Dexamethasone Phosphate

EEyegate Pharmaceuticals, Inc.

Phase 3

1 2

Ripasudil

KKowa Research Institute, Inc.

Phase 3

2 3

Idose TR

GGlaukos Corporation

Phase 3

1 4

OCS-01

QQuan Dong Nguyen

Phase 3

1 5

Zolymbus

AbbVie

Preclinical

—6

Neurontin

VViatris Specialty LLC

Preclinical

3 7

Kenalog

BBassett Healthcare

Preclinical

1 8

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 9

Duragesic

CCephalon

Preclinical

1 10

Bactroban

PPadagis LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cataract2 trials

A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

Completed·MMelt Pharmaceuticals·Phase 2·NCT05133518·338 enrolled

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

Recruiting·MMelt Pharmaceuticals·Phase 3·NCT06383273·528 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MELT-300. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MELT-300 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MELT-300. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Melt Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMelt Pharmaceuticals

MELT-300

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cataract2 trials

References

Drug Info

Quick Facts

Related News